Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.30 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5139796 | 1.00 | BACE1 (0.34) | BACE1CYP4F2CYP4A11CACNA1HPDE2A | |
| SCHEMBL2628504 | 0.90 | PTPN1 (0.35) | BACE1CYP4F2CYP4A11CACNA1HMEN1 | |
| SCHEMBL3577732 | 0.81 | CTSS (0.42) | BACE1ALDH1A1LMNAHTTPPARG | |
| SCHEMBL1799692 | 0.77 | CYP3A4 (0.45) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2079320 | 0.77 | CTSB (0.42) | — | |
| SCHEMBL4344357 | 0.73 | PTGES (0.34) | BACE1 | |
| SCHEMBL4344352 | 0.73 | PTGES (0.34) | BACE1 | |
| SCHEMBL4352424 | 0.71 | KDM4E (0.35) | BACE1ALDH1A1 | |
| SCHEMBL2175747 | 0.68 | CTSS (0.42) | BACE1ALDH1A1LMNAHTTPPARG | |
| SCHEMBL12619106 | 0.68 | FAAH (0.36) | PDE2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552181-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8163909-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008147547-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275602-A1 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | BACE1, BACE2, APP | BACE1 1/4885CYP4F2 1741/4885CYP4A11 916/4885 |
| US-20120220583-A1 | SUBSTITUTED HYDROXYETHYL AMINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | BACE1 1/4885CYP4F2 2645/4885CYP4A11 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.